Drug · CHEMBL81
RALOXIFENE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RALOXIFENE. Drugs and targets, record CHEMBL81. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL81
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Eviden, J22.982B, Keoxifene, LY-139481, NSC-747974, Raloxifeno, Raloxiphene, Raxeto
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 16 diseases, from EMA Human Drugs and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ESR1 | Estrogen receptor | Estrogen receptor modulator | MODULATOR | https://conductscience.org/library/genes/2099 |
| ESR2 | Estrogen receptor beta | Estrogen receptor beta modulator | MODULATOR | https://conductscience.org/library/genes/2100 |
Source ChEMBL
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials63
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00687102 | Cognition in the Study of Tamoxifen and Raloxifene | Phase 3 | 1,498 | 2018-01-23 | raloxifene | Its name | ClinicalTrials.gov |
| NCT00723398 | Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention | 266 | 2018-11-01 | raloxifene | Its name | ClinicalTrials.gov | |
| NCT00431444 | Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density | Phase 4 | 110 | 2011-03-11 | raloxifene | Its name | ClinicalTrials.gov |
| NCT00427700 | Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome | Phase 3 | 82 | 2016-10-06 | raloxifene | Its name | ClinicalTrials.gov |
| NCT00030147 | Raloxifene and Rimostil for Perimenopause-Related Depression | Phase 4 | 65 | 2016-09-05 | raloxifene | Its name | ClinicalTrials.gov |
| NCT05172050 | Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. | Phase 2/3 | 61 | 2023-12-14 | raloxifene | Its name | ClinicalTrials.gov |
| NCT00368459 | Raloxifene for Women With Alzheimer's Disease | Phase 2 | 42 | 2015-04-02 | raloxifene | Its name | ClinicalTrials.gov |
| NCT01166958 | Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? | Phase 4 | 26 | 2014-09-22 | raloxifene | Its name | ClinicalTrials.gov |
| NCT01607320 | Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome | 3 | 2015-06-01 | raloxifene | Its name | ClinicalTrials.gov | |
| NCT01077817 | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352) | 684,815 | 2013-05-01 | raloxifene | Its name | ClinicalTrials.gov |
1 to 10 of 63
See all 63 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Star Participants Assigned to Tamoxifen vs Star Participants Assigned to Raloxifene: serious adverse events | 0 of 733 | 0 of 765 | 1,498 | NCT00687102 | Trial comparisons |
| Zoledronic Acid vs Raloxifene: serious adverse events | 1 of 56 | 1 of 53 | 109 | NCT00431444 | Trial comparisons |
| Clomiphene Citrate vs Raloxifene: serious adverse events | 0 of 40 | 0 of 42 | 82 | NCT00427700 | Trial comparisons |
| Raloxifene vs Placebo: serious adverse events | 2 of 21 | 1 of 21 | 42 | NCT00368459 | Trial comparisons |
| Daily Teriparatide (Forteo) vs Monthly Cycles of Teriparatide Followed by Raloxifene: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01166958 | Trial comparisons |
Papers from its trials39
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Fluency | 2 | 0 | ConductCognition |
| Verbal Learning | 2 | 1 | ConductCognition |
| Category Fluency | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Finger Tapping Task | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL81
GET https://conductscience.org/api/drugs/v1/CHEMBL81/trials?page=2